drugset / Trial / NCT05722327
Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
Phase 1
Active not recruiting
24 enrolled
M.D. Anderson Cancer Center
Mirati Therapeutics Inc. · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
To find the recommended dose of MRTX849 that can be given in combination with cetuximab and irinotecan to patients with colorectal cancer that have a mutation (genetic change) called KRAS G12C.
Timeline
- Start
- 2023-12-06
- Primary completion
- 2027-09-30
- Completion
- 2027-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adagrasib | Small molecule | — | Oral |
| Subject | Irinotecan | Small molecule | — | Intravenous |
| Background | Cetuximab | Monoclonal antibody | — | Intravenous |